You are here

AstraZeneca

The problem with Her2-low testing

EP Vantage

Mon, 11/28/22 - 07:34 pm

HER2-low breast cancer

AstraZeneca, C4XD sign exclusive $402 million global license

Pharmaphorum

Mon, 11/28/22 - 10:20 am

drug development

Pulling back the curtain on AstraZeneca’s CAR-T work

EP Vantage

Fri, 11/18/22 - 10:23 am

GSK, J&J and AZ top global drug access index, but foundation says plenty more work needs to be done

Fierce Pharma

Thu, 11/17/22 - 12:13 pm

Access to Medicine Foundation

AstraZeneca Launches Phase II Trial of Anti-TIGIT NSCLC Therapy

BioSpace

Wed, 11/16/22 - 11:24 pm

clinical trials

non-small lung cancer

AstraZeneca and Sanofi win big as Europe's human medicines committee endorses approvals, label expansions

Fierce Pharma

Mon, 11/14/22 - 07:10 pm

AZ claims another Imjudo approval, in big first-line NSCLC market

Pharmaphorum

Fri, 11/11/22 - 10:53 am

non-small cell lung cancer

AstraZeneca total revenue soars 19% in Q3

Medical Marketing and Media

Thu, 11/10/22 - 10:18 pm

AstraZeneca withdraws US COVID vaccine application, shifts focus to antibody treatments

Fierce Pharma

Thu, 11/10/22 - 10:37 am

Yes, no, maybe: FDA panel delivers mixed verdict on AstraZeneca's asthma rescue medication

Fierce Biotech

Wed, 11/9/22 - 10:43 am

Eli Lilly, Boehringer Ingelheim bolster case for Jardiance to treat chronic kidney disease

Fierce Pharma

Sun, 11/6/22 - 01:44 pm

Boehringer Ingelheim

chronic kideny disease

AstraZeneca hands omnichannel ops mandate to Indegene

Medical Marketing and Media

Sun, 11/6/22 - 01:39 pm

Sanofi, AstraZeneca clinch first OK for RSV antibody — just as vaccines line up at regulators

Endpoints

Fri, 11/4/22 - 10:21 am

AstraZeneca password lapse exposed patient data

TechCrunch

Thu, 11/3/22 - 07:27 pm

If at first... pharma’s most drawn-out development timelines revealed

EP Vantage

Thu, 11/3/22 - 10:54 am

Eiger BioPharmaceuticals

Teva Pharmaceutical

Bavarian Nordic

drug development

Daiichi Sankyo sets new highs for AstraZeneca-partnered cancer drug Enhertu

Endpoints

Mon, 10/31/22 - 04:15 pm

non-small cell lung cancer

AstraZeneca beats Roche twice in a day

EP Vantage

Wed, 10/26/22 - 10:20 am

Weak data for Fasenra undermine AZ’s ambitions for the drug

Pharmaphorum

Tue, 10/25/22 - 10:35 am

eosinophilic asthma

chronic rhinosinusitis with nasal polyps

eosinophilic esophagitis

Novartis, eyeing $3B market, beats AstraZeneca blood disorder blockbusters in phase 3

Fierce Biotech

Mon, 10/24/22 - 11:17 pm

clinical trials

Charles River cuts the ribbon on former AstraZeneca site in the UK for plasmid manufacturing

Endpoints

Thu, 10/20/22 - 10:36 am

Charles River Labs

drug manufacturing

Pages